New Zealand's PHARMAC seeks info to support use of enzyme replacement therapies
This article was originally published in Scrip
PHARMAC, the pharmaceutical management agency of New Zealand, has asked for more information on enzyme replacement therapies (ERTs) for lysosomal storage disorders, before it can decide whether to fund them through its Pharmaceutical Schedule (a full list of all pharmaceuticals approved for funding in New Zealand). PHARMAC's role is to manage the Pharmaceutical Schedule to ensure the best drugs within budget are available to New Zealanders. The organisation says there is only "weak evidence" to support funding applications for expensive lysosomal storage disorder therapies, including ERTs, and it wants further details of the treatments' effectiveness to help its assessment.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.